Nordic Laboratories

PATIENT: XXXXXXXXXXXXXXXXXXX			TEST REF: TST-NL-XXXXX
TEST NUMBER: T-NL-XXXXXX	COLLECTED: 2025-XX-XX		PRACTITIONER: XXXXXXXXXXXXXXXXXXX
GENDER: XXXXX	RECEIVED: 2025-XX-XX		
AGE: XX	TESTED: 2025-XX-XX		XXXXXXXXXXXXXXXXX

TEST NAME: Cardiovascular Risk Profile

Cardiovascular Risk Profile; serum

LIPIDS/RATIOS	RESULT / UNIT	REFERENCE INTERVAL
Total Cholesterol	288 mg/dL	< 200
Triglycerides	144 mg/dL	< 150
HDL Cholesterol	59 mg/dL	> 50
LDL Cholesterol (calculated)	203 mg/dL	< 100
VLDL Cholesterol (calculated)	30.0 mg/dL	< 30.0
Non-HDL Cholesterol (calculated)	229 mg/dL	< 130
OxLDL Cholesterol	83 U/L	< 60
sdLDL Cholesterol (calculated)	63 mg/dL	< 35
Lp(a)	98 mg/dL	< 30
Total Cholesterol : HDL-C	4.9	< 4.0
LDL-C : HDL-C	3.4	< 2.0
OxLDL-C: LDL-C	0.41	< 0.45
sdLDL-C : LDL-C	0.31	< 0.34
Apo B : Apo A-1	1.0	< 0.80
RISK FACTORS/INFLAMMATORY MARKERS		
PLAC (LP-PLA$_2$ Activity)	223 U/L	< 151
Homocysteine	18.7 µmol/L	< 11.0
hsCRP	1.1 mg/L	< 1.0
APOLIPOPROTEINS		
Apolipoprotein A-1	150 mg/dL	115- 220
Apolipoprotein B	157 mg/dL	50- 130



SPECIMEN DATA

Comments:
Date Collected: 10/07/2025 Time Collected:
Date Received: 10/10/2025 Fasting:
Date Completed: 10/15/2025 BMI: N/A
Methodology: Immunoturbidimetric Assay

<dl: less than detection limit

Nordic Laboratories Aps
Nygade 6, 3.sal • 1164 Copenhagen K • Denmark
Tlf. +45 33 75 10 00

UK Office:
11 Old Factory Buildings • Stonegate • E. Sussex TN5 7DU • UK
Tel: +44 (0)1580 201 687

www.nordic-labs.com
info@nordic-labs.com

TEST NAME: Cardiovascular Risk Profile

Total Cholesterol High

The level of plasma total cholesterol in this sample is higher than expected. A high level of plasma total cholesterol has been long considered to an independent risk factor for CVD. Modern day research indicates that much more sensitive CVD risk factors include small dense LDL (sdLDL) cholesterol, the ratio of sdLDL cholesterol to LDL cholesterol, non-HDL cholesterol, and the ratio of LDL to HDL cholesterol.

Dietary changes, in addition to other lifestyle modifications, may help reduce total cholesterol.

Total cholesterol levels may be lowered by reducing the consumption of saturated fat, and increasing consumption of omega-3 fatty acids (e.g. fish oil, algae oil).

LDL Cholesterol High

The level of low-density lipoprotein cholesterol (LDL-C) in this sample is higher than expected. LDL-C has long been considered to be an independent risk factor for CVD. However recent research indicates that sub-species of LDL pose a better indication of risk when LDL particles are metabolized to sdLDL and oxidized LDL (ox-LDL). The levels of sd LDL-C and oxidized LDL are not correlated with the level of LDL-C therefore all three factors should be considered in the assessment of CVD risk.

Statin drugs reduce high levels of LDL-C by inhibiting the enzyme HMG-CoA reductase which is the rate-limiting step in cholesterol biosynthesis, but also inhibit production of CoQ10. Supplementation with CoQ10 is essential with use of statin drugs. High LDL-C levels may be lowered by consumption of an appropriate amount of omega-3 fatty acids from fish oil. Niacin (vitamin B3) may lower LDL-C by decreasing the hepatic secretion of precursor very low density lipoproteins.

Oxidized LDL High

A high level of oxidized LDL (oxLDL) is a strong predictor of risk for coronary artery disease (CAD), and increasing levels of oxLDL are incrementally associated with the severity of CAD. High levels of oxLDL also markedly increase the risk for developing metabolic syndrome well within a decade.

The apo B protein constituent is oxidized when LDL particles (predominantly small dense LDL) penetrate the arterial wall. The modified apo B protein is then recognized as foreign, taken up in an unregulated manor by the scavenger receptors on resident macrophages. That process instigates an arterial inflammatory response with further recruitment of monocytes, and the initiation of foam cells. Oxidized LDL interacts with PLAC (Lp-PLAC2), which increases inflammation and enhances a pro-atherogenic state, as well as plaque vulnerability.

Small dense LDL Cholesterol High

Small dense LDL (sdLDL) is an extremely atherogenic LDL subtype that is associated with about 3-times greater risk for CVD than normal-size LDL particles. SdLDL-C levels are also independently associated with increased risk for Type-II diabetes. SdLDL-C is associated with elevated triglycerides and low HDL-C (mechanistically), obesity, metabolic syndrome, pre-diabetes, insulin resistance, renal dysfunction, hepatic steatosis and dietary trans-fatty acids.

Nordic Laboratories Aps
Nygade 6, 3.sal • 1164 Copenhagen K • Denmark
Tlf. +45 33 75 10 00

UK Office:
11 Old Factory Buildings • Stonegate • E. Sussex TN5 7DU • UK
Tel: +44 (0)1580 201 687

www.nordic-labs.com
info@nordic-labs.com

The level of sdLDL-C is not proportional to the level of total LDL-C. The sdLDL more readily penetrate the arterial endothelial wall and are more prone to oxidation.

Elevated sdLDL-C may be lowered with lifestyle modifications and niacin that lower TG levels, as well appropriate control of blood glucose. Pharmaceuticals that lower sdLDL-C include, fenofibrate and combinations of fibrates and statins.

Lp(a) High

Lp(a) is cholesteryl ester-rich LDL sub-species that contains an apo (a) protein attached to apo B. It is a genetically determined lipoprotein that has potent atherogenic and thrombogenic properties. Lp(a) levels can be elevated with an otherwise normal lipid and lipoprotein profile, and are associated with ischemic stroke and carotid artery atherosclerosis. Elevated Lp(a) levels indicate increased risk increased risk for CHD and myocardial infarction. Lp(a) levels are only slightly affected by diet, exercise, fish oil, and commonly prescribed lipid-lowering drugs have little or no effect on Lp(a) levels.

Total Cholesterol : HDL-C High

A high ratio of plasma total cholesterol (TC) to high-density lipoprotein cholesterol (HDL-C) is considered to be a CVD risk factor. Blood cholesterol is transported predominantly by low-density lipoproteins (LDL) and high-density lipoproteins (HDL). The majority of circulating TC is associated of LDL, and an elevated level of TC is considered to be CVD risk factors. HDL-C is inversely associated with CVD risk. The clinical significance of a level of TC is more predictive when viewed in context with the associated level of anti-atherogenic HDL-C.

LDL-C : HDL-C High

The ratio of low-density lipoprotein cholesterol (LDL-C) to high-density lipoprotein cholesterol (HDL-C) is higher than expected in this sample. The LDL-C: HDL-C ratio is considered to be a CVD risk factor. Plasma cholesterol is transported predominantly by low-density (LDL) and to a lesser extent by high-density lipoproteins (HDL). The majority of total cholesterol is associated within the hydrophobic core of LDL and LDL-C is considered to be CVD risk factor. HDL-C is inversely associated with CVD risk but the clinical significance of the level of HDL-C has more value when viewed in context with LDL-C. For example if one has a normal level of HDL-C but an elevated level of LDL-C the predictive value of that level of HDL-C may be significantly marginalized.

ApoB : ApoA1 Ratio High

A high ratio of apo B to apo-A1 is a very strong risk factor for CVD and acute myocardial infraction. Apo B levels provide a direct indication of the particle number of all atherogenic non-HDL lipoproteins, including VLDL, IDL, Lp(a) and LDL. Apo-A1 provides a direct indication of anti-atherogenic HDL particles. Therefore the apo B to apo-A1 ratio provides functional insight into so called cholesterol balance, or estimation of net reverse cholesterol transport.

Nordic Laboratories Aps
Nygade 6, 3.sal • 1164 Copenhagen K • Denmark
Tlf. +45 33 75 10 00

UK Office:
11 Old Factory Buildings • Stonegate • E. Sussex TN5 7DU • UK
Tel: +44 (0)1580 201 687

www.nordic-labs.com
info@nordic-labs.com

TEST NAME: Cardiovascular Risk Profile

Homocysteine High

High levels of serum homocysteine have long been thought to be an independent risk factor for CVD. Consensus has changed as a result of further evaluation, and presently homocysteine may be regarded as a weak risk factor for coronary heart disease. There is a lack of direct causal relationship between hyperhomocysteinemia and CVD. However elevated levels of homocysteine indicate significant disruption of essential methionine metabolism that can impair all essential methylation reactions, and impair the transsulfuration pathway with potentially diminished redox potential and increased oxidative stress. Methionine metabolism can be disrupted by genetic and epigenetic factors; the latter include deficiencies of vitamins B-6, B-12 and folate. The Plasma Methylation Profile can help identify causes of disrupted methionine and folate metabolism.

Elevated hsCRP

An elevated level of hsCRP is a well-established indicator of arterial inflammation that is associated with substantial risk of coronary artery disease and cardiovascular events. It is an independent risk factor for future heart attack, stroke and death for asymptomatic men and woman. Elevated CRP has also been related to risk for metabolic syndrome; it tracks well with a high leptin to adiponectin ratio. Reductions in hsCRP levels along with other CVD risk factors such as non-HDL cholesterol levels has been associated with decreased progression of atherosclerosis and better clinical outcomes.

Guidelines for cardiovascular risk related to levels of CRP are: moderate; 1-3 mg/dL, high; 3-10 mg/dL. Levels greater than 10 are likely associated with non-cardiovascular inflammation (e.g. acute infection), and the hsCRP test should be repeated in about three weeks. Some suggested interventions to lower hsCRP levels include statins, decreasing adiposity, aspirin, and low-dose methotrexate.

Apolipoprotein B High

A high level of apolipoprotein B (apo B) is a strong risk factor for CVD. Further, elevated levels of Apo B appear to indicate increased risk of fatal MI even when LDL levels are within normal. Elevated apo B is a better indicator of risk for CVD than either total cholesterol or LDL-cholesterol levels.

Apo B is the only protein constituent of low-density lipoproteins (LDL); apo B is also a component of all atherogenic non-HDL particles including very low density lipoproteins, intermediate density lipoproteins, Lp(a) and lipoprotein remnant particles. As such apo B levels provide a relative indication of atherogenic lipoprotein particle number.

Non-HDL Cholesterol High

A high level of non-HDL cholesterol (NHDL-C) is a stronger CVD risk factor than LDL or triglycerides for patients with high triglycerides or diabetes. NHDL-C has become the new ”bad cholesterol,” as it reflects the sum of serum cholesterol carried by all of the potentially atherogenic apo-B containing lipoproteins including LDL, VLDL, IDL, Lp(a) and other remnant lipoproteins. Reductions in NHDL-C may improve endothelial function and reduce inflammatory reactions that contribute to atherosclerosis. NHDL-C is calculated from direct measurement of total and HDL cholesterol levels and is not influenced by serum triglyceride levels.

Nordic Laboratories Aps
Nygade 6, 3.sal • 1164 Copenhagen K • Denmark
Tlf. +45 33 75 10 00

UK Office:
11 Old Factory Buildings • Stonegate • E. Sussex TN5 7DU • UK
Tel: +44 (0)1580 201 687

www.nordic-labs.com
info@nordic-labs.com

TEST NAME: Cardiovascular Risk Profile

The recommended NHDL-C goal of less than 130 mg/dL is higher than the LDL-C target of 100 mg/dL.

PLAC High

High levels of lipoprotein phospholipase A2 activity (PLAC) are associated with increased risk of coronary artery disease (CAD) disease progression, plaque instability and cardiovascular events. High PLAC is indicative of very significant atherogenic disease activity within coronary arteries and increased risk for rupture of advanced plaque. High levels of PLAC are associated with double the risk of CAD regardless of the level of atherogenic non-HDL cholesterol levels, as well as a higher risk for myocardial infarction and CAD-related morbidity and mortality. PLAC interacts with oxidized LDL. It participates in the breakdown of oxidized LDL in the vascular wall by hydrolyzing the oxidized phospholipid, producing lysophosphatidycholine and oxidized free fatty acids, both of which are potent pro-inflammatory products that contribute to the formation of atherosclerotic plaques.

PLAC is bound primarily to circulating LDL, and is enriched in atherosclerotic plaque. Lipid-laden macrophages within the artery release PLAC, further inflammation ensues, and calcified athero-sclerotic plaques become unstable. Clinical management may include beginning or intensifying risk reduction strategies.

Nordic Laboratories Aps
Nygade 6, 3.sal • 1164 Copenhagen K • Denmark
Tlf. +45 33 75 10 00

UK Office:
11 Old Factory Buildings • Stonegate • E. Sussex TN5 7DU • UK
Tel: +44 (0)1580 201 687

www.nordic-labs.com
info@nordic-labs.com